Equivalentes de esteroides pdf

Serious adverse events (SAEs) occurred at a 40 percent rate for patients receiving Avastin and a 32 percent rate for patients receiving Lucentis. Although Avastin had a higher rate of SAEs, they were distributed across many different conditions, most of which were not associated with Avastin when evaluated in cancer clinical trials, in which the drug was administered at 500 times the dose used for AMD. Fewer doses were associated with a higher rate of SAEs, which is not a typical dose-response relationship. The number of deaths, heart attacks, and strokes were low and similar for both drugs during the study. CATT was not capable of determining whether there is an association between a particular adverse event and treatment.  Additional data from other clinical trials may provide information on long-term safety profiles of these drugs when used to treat AMD.

Equivalentes de esteroides pdf

equivalentes de esteroides pdf

Media:

equivalentes de esteroides pdfequivalentes de esteroides pdfequivalentes de esteroides pdfequivalentes de esteroides pdfequivalentes de esteroides pdf